New York, February 6, 2026, 11:57 EST — Regular session

• Merck shares rose nearly 2% in midday trade, extending a multi-day climb.
• Health Canada cleared Merck’s RSV preventive ENFLONSIA for newborns and infants.
• Investors are watching an FDA action date later this month tied to Keytruda.

Merck & Co. shares rose 1.8% to $121.92 on Friday, after trading as high as $122.65 earlier in the session. The stock had opened at $121.01.

The move came with a broad rebound across U.S. equities and healthcare, a pocket that tends to draw bids when risk appetite gets shaky. The SPDR S&P 500 ETF gained about 1.5% and the Health Care Select Sector SPDR was up about the same in midday trading.

Merck’s shares were also…